The recent letter to the shareholders by the CEO of Muscle Pharm underlined the company's focus and desire to turn around and improve its cost structure. Without controlling the cost, the exponential growth is of little use. As mentioned in the communication, the debt is being reduced and the supply chain inefficiencies are being tackled. Further, the reason for recent consolidation (1:82) of shares was clarified. Basically the intention is to improve ease of receiving equity funding from institutional investors by getting listed on major stock exchanges. As per the management, the listing is likely to happen within 2013, in fact, after the first quarter results are declared. Sales in 4th quarter of 2012 was around $27M which indicates that the rate of growth is still breathtaking. Now that cost control is on top of the agenda, the company seems to be getting on the right track. Better operations management will help improve gross margins. Reduced debt (in fact, zero debt) would mean very low interest payments thereby improving net margins. Further, a debt free company is more likely to attract equity investment, and at better terms / rates. Both these combined together would reduce working capital requirement thereby reducing funding requirement. Regarding reducing costs, one suggestion could be to focus more on the segments or markets where the costing is better and reduce presence in other, less favorable markets. One-fifth of the sales of MSLP come from overseas markets. The timing of the letter and the mention of possible listing on the exchanges immediately after upcoming results in April indicates confidence of the management on what can be expected. In Q1'13, the balance sheet can be expected to be cleaner and some improvement on the margins front can be expected. Perhaps, the MSLP management knows this and is planning to leverage the changed scenario to attract investment from some big guys (again).